The data showed that viral loads were below the lower limit of quantification for 80% (37/46) of patients with genotype 1 hepatitis C at week two and 83% (38/46) of patients with genotype 1 at week 12.
Eleven patients met the criteria of having undetectable hepatitis C virus at weeks two and eight of treatment and were therefore eligible to stop all treatment at 12 weeks.
Nine of these 11 patients achieved SVR4 (undetectable hepatitis C virus four weeks after the end of all treatment), the company said.
The three drug regimen was generally well-tolerated.